HCA Healthcare, Inc. $HCA Shares Sold by Genus Capital Management Inc.

Genus Capital Management Inc. trimmed its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 21.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,680 shares of the company’s stock after selling 3,420 shares during the period. Genus Capital Management Inc.’s holdings in HCA Healthcare were worth $4,858,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HCA. Cheviot Value Management LLC acquired a new stake in shares of HCA Healthcare during the 1st quarter worth $26,000. Saudi Central Bank acquired a new stake in HCA Healthcare in the 1st quarter valued at $26,000. WPG Advisers LLC purchased a new stake in shares of HCA Healthcare during the 1st quarter valued at about $27,000. Ameriflex Group Inc. purchased a new stake in shares of HCA Healthcare during the 2nd quarter valued at about $27,000. Finally, Chung Wu Investment Group LLC purchased a new stake in shares of HCA Healthcare during the 2nd quarter valued at about $27,000. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Stock Up 2.1%

Shares of HCA stock opened at $471.44 on Wednesday. The business has a 50 day moving average of $423.66 and a two-hundred day moving average of $389.09. HCA Healthcare, Inc. has a 52 week low of $289.98 and a 52 week high of $478.19. The company has a market cap of $110.31 billion, a P/E ratio of 18.22, a PEG ratio of 1.38 and a beta of 1.40.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $1.32. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The company had revenue of $19.16 billion during the quarter, compared to the consensus estimate of $18.55 billion. During the same period in the previous year, the firm posted $4.90 earnings per share. HCA Healthcare’s quarterly revenue was up 9.6% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. Analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, December 15th. HCA Healthcare’s payout ratio is 11.13%.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at approximately $13,194,716.52. The trade was a 10.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on HCA. Sanford C. Bernstein reiterated a “market perform” rating and set a $417.00 target price on shares of HCA Healthcare in a report on Monday, October 27th. Barclays raised their target price on HCA Healthcare from $445.00 to $494.00 and gave the company an “overweight” rating in a research note on Monday, October 27th. Jefferies Financial Group raised their target price on HCA Healthcare from $485.00 to $525.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. TD Cowen raised their target price on HCA Healthcare from $380.00 to $490.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Finally, KeyCorp raised their target price on HCA Healthcare from $465.00 to $475.00 and gave the company an “overweight” rating in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $473.53.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.